Effect of Ritlecitinib on PK of Caffeine

Jian Liu,¹ Rohit Solan,² Robert Wolk,³ Anna Plotka,⁴ Melissa T. O’Gorman,⁵ Jennifer A. Winton,⁵Julia Kaplan,⁶ Vivek S. Purohit⁵

Affiliations: ¹Clinical Pharmacology, Pfizer Investment Co., LTD, Beijing, China; ²Pfizer Research & Development UK Limited, Hurley, UK; ³Pfizer Global Research & Development, Groton, CT, USA;⁴Biostatistics, Pfizer Inc, Collegeville, PA, USA;⁵Clinical Pharmacology, Pfizer Inc, Groton, CT, USA;⁶Pfizer Inc, La Jolla, CA, USA

Corresponding author:

Jian Liu

9/F, Tower B, Minmetals Plaza, Dongcheng District

Beijing, China 100010

Tel: + 8610-8516 7429

E-mail: jian.liu2@pfizer.com

Key words: ritlecitinib, drug interaction, CYP1A2, caffeine, PK

Target journal: British Journal of Pharmacology

Character count for title (including spaces): 100/150

Character count for short title (including spaces): 40/40

Word count for article: 2689/4000

Word count for abstract: 233/250

References: 22/no limit

Figures/tables: 6/8